Agios reports Phase I safety data for IDH1/IDH2 inhibitor

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) reported safety data from 93 evaluable patients in a Phase I trial evaluating AG-881 to treat advanced

Read the full 212 word article

User Sign In